Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
430C10
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
430C10 is a first-in-class, orally active small molecule FOXP3-targeting stabilizer. Identified through an AI-driven virtual screening strategy, 430C10 binds to an allosteric pocket within the forkhead (FKH) domain of FOXP3. This binding reinforces the physical interaction between FOXP3 and T-bet, thereby suppressing T-bet-driven interferon-gamma (IFN-γ) production by regulatory T cells (Tregs) and restoring Treg stability. 430C10 is being investigated for the treatment of IPEX (immunodysregulation polyendocrinopathy enteropathy X-linked) syndrome, acute colitis, and other IFN-γ-driven autoimmune and inflammatory diseases.
02
Targets
FOXP3 (Forkhead box protein P3)
Beyond the preview
Go deeper on 430C10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 430C10.